Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects

Next Previous
X
Search
Trial Profile

Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fosamprenavir (Primary) ; Ritonavir (Primary) ; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MERIT
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK; ViiV Healthcare

    • Most Recent Events

    • 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
    • 27 Apr 2012 Company (ViiV Healthcare) added as trial sponsor as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Patient number amended from 206 to 212 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top